USC.edu
Are you a Patient?

W. Martin Kast, PhD

Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology, Urology, and Otolaryngology-Head & Neck Surgery

Walter A. Richter Cancer Research Chair

Director Medical Biology Graduate Program

Image of W. Martin Kast, PhD
Websites
Is this your profile? Click to edit
Phone +1 323 442 3870
Email Martin.Kast@med.usc.edu
Orcid ID CTSI Profile

Overview

W. Martin Kast, PhD is a Professor of Molecular Microbiology & Immunology, Obstetrics & Gynecology, Urology and Otolaryngology at the Norris Comprehensive Cancer Center (NCCC) of the University of Southern California in Los Angeles, CA. He holds the Walter A. Richter Cancer Research Chair and is the Director of the NCCC Tumor Micro-environment program, the Director of the USC Medical Biology & Infectious Diseases Immunology and Pathogenesis Graduate Programs, the Director of the Beckman Center for Immune Monitoring, the Director of the K-12 Cancer Education Program and the Associate Dean of Academic Integrity. A native of the Netherlands, he earned his BS, MS, and PhD summa cum laude, from the University of Amsterdam in the Netherlands. He is serving on multiple Study Sections including the National Institute of Health and the Cancer Prevention and Research Institute of Texas. His research involves the design of therapeutic cancer vaccines directed against human papilloma virus (HPV) and prostate cancer. Several of his therapeutic HPV vaccines hare currently been tried out in clinical trials. He studies HPV cell entry and the interaction of HPV with the human immune system to find out how HPV escapes immune detection and how to reverse that. He has published 286 articles that have been quoted more than 27,500 times and led to a publication h-index of 85. He is also the inventor on 18 patents. His research is supported by NIH grants. He is an editor for the journal Cancers. He also served as the secretary/treasurer of the International Papillomavirus Society from 2012-2019 and serves on the advisory board of 6 biotechnology companies. In October 2022, he published a book entitled Oncology that is meant for Elementary Schools serving underrepresented minority students together with his daughter Dr. Dieuwertje J. Kast. In his free time he is a Scoutmaster and an actor.

Awards

  • USC Stevens Center for Innovation : Commercialization Award, 2021
  • University of Southern California: Graduate Student Mentoring Award, 2021
  • 10XGenomics: 10XGenomics Prize, 2021
  • Society of Immunotherapy of Cancer: Team Science Award, 2020
  • University of Southern California: Dornsife Award for Exceptional Service, 2019
  • Affymetrix: Affymetrix Prize, 2016
  • Rare Genomics Institute: BeHeard Ultimate Prize, 2015
  • STOP Cancer: STOP Cancer Award, 2015
  • University of Southern California: Mellon Award for Graduate Student Mentoring, 2014
  • University of Amsterdam: Landsteiner Prize, 2012
  • Royal Netherlands Academy of Arts and Sciences: Royal Netherlands Academy of Arts & Sciences Award, 1991-1995
  • Netherlands Cancer Institute: Antoni van Leeuwenhoek Prize, 1991

Publications

  • Understanding medical mistrust and HPV vaccine hesitancy among multiethnic parents in Los Angeles J Behav Med. 2023 04; 46(1-2):100-115. . View in PubMed
  • Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer Front Immunol. 2023; 14:1268117. . View in PubMed
  • Diversity of Anal HPV and Non-HPV Sexually Transmitted Infections and Concordance with Genital Infections in HIV-Infected and HIV-Uninfected Women in the Tapajós Region, Amazon, Brazil Viruses. 2023 06 06; 15(6). . View in PubMed
  • Examining multilevel influences on parental HPV vaccine hesitancy among multiethnic communities in Los Angeles: a qualitative analysis BMC Public Health. 2023 03 22; 23(1):545. . View in PubMed
  • Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus Cancers (Basel). 2022 Sep 05; 14(17). . View in PubMed
  • Single-cell genomics identifies immune response to neoadjuvant chemoradiotherapy EBioMedicine. 2022 12; 86:104389. . View in PubMed
  • Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials Cancer Treat Rev. 2022 05; 106:102385. . View in PubMed
  • Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors Cancer Immunol Res. 2020 07; 8(7):856-868. . View in PubMed
  • The Essential Role of anxA2 in Langerhans Cell Birbeck Granules Formation Cells. 2020 04 15; 9(4). . View in PubMed
  • Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) Clin Cancer Res. 2020 11 01; 26(21):5621-5630. . View in PubMed
  • Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering Front Immunol. 2020; 11:561843. . View in PubMed
  • Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy Oncoimmunology. 2020 11 29; 9(1):1851539. . View in PubMed
  • TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy Front Immunol. 2020; 11:922. . View in PubMed
  • Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease Vaccine. 2019 05 16; 37(22):2915-2924. . View in PubMed
  • Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study BMC Cancer. 2018 Oct 11; 18(1):970. . View in PubMed
  • Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors Gynecol Oncol. 2018 10; 151(1):102-110. . View in PubMed
  • Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses Cancer Immunol Res. 2018 07; 6(7):870-880. . View in PubMed
  • Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response PLoS One. 2018; 13(1):e0191311. . View in PubMed
  • Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation Sci Rep. 2018 08 03; 8(1):11642. . View in PubMed
  • Annexin A2 in Virus Infection Front Microbiol. 2018; 9:2954. . View in PubMed
  • Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy Oncotarget. 2017 Sep 26; 8(43):74378-74390. . View in PubMed
  • Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions Papillomavirus Res. 2017 12; 4:90-98. . View in PubMed
  • A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression Front Immunol. 2017; 8:563. . View in PubMed
  • The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis J Virol. 2016 Dec 01; 90(23):10629-10641. . View in PubMed
  • Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed
  • T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation Papillomavirus Res. 2016 12; 2:21-30. . View in PubMed
  • Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment AIDS Patient Care STDS. 2016 07; 30(7):291-306. . View in PubMed
  • Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells J Interferon Cytokine Res. 2016 05; 36(5):291-301. . View in PubMed
  • Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. . View in PubMed
  • Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 11 18; 13(1):187. . View in PubMed
  • Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients J Acquir Immune Defic Syndr. 2016 09 01; 73(1):27-33. . View in PubMed
  • Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4 J Neuroimmunol. 2016 10 15; 299:70-78. . View in PubMed
  • Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin Immunol. 2015 Dec; 161(2):197-208. . View in PubMed
  • Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C Papillomavirus Res. 2015 Dec 01; 1:12-21. . View in PubMed
  • A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours J Gen Virol. 2015 Sep; 96(9):2764-2768. . View in PubMed
  • Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in PubMed
  • Functional analysis of HPV-like particle-activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:333-50. . View in PubMed
  • Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection J Antimicrob Chemother. 2015; 70(6):1686-90. . View in PubMed
  • Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:135-49. . View in PubMed
  • Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression J Immunol. 2014 May 15; 192(10):4748-57. . View in PubMed
  • Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype Virology. 2014 Mar; 452-453:279-86. . View in PubMed
  • The evolving field of human papillomavirus receptor research: a review of binding and entry J Virol. 2013 Jun; 87(11):6062-72. . View in PubMed
  • Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor Oncol Rep. 2013 May; 29(5):1962-8. . View in PubMed
  • A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies J Transl Med. 2012 Nov 05; 10:218. . View in PubMed
  • Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability Int Rev Immunol. 2012 Oct; 31(5):302-20. . View in PubMed
  • Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia J Pathol. 2012 Apr; 226(5):713-22. . View in PubMed
  • Perspective for prophylaxis and treatment of cervical cancer: an immunological approach Int Rev Immunol. 2012 Feb; 31(1):3-21. . View in PubMed
  • In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more Int Rev Immunol. 2012 Feb; 31(1):1-2. . View in PubMed
  • Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma Int Rev Immunol. 2012 Feb; 31(1):22-42. . View in PubMed
  • The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection PLoS One. 2012; 7(8):e43519. . View in PubMed
  • Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer Prostate. 2012 Jan; 72(1):12-23. . View in PubMed
  • Notch-ing from T-cell to B-cell lymphoid malignancies Cancer Lett. 2011 Sep 01; 308(1):1-13. . View in PubMed
  • Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy J Immunother. 2011 Jul-Aug; 34(6):490-9. . View in PubMed
  • The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma Int J Oncol. 2011 Jul; 39(1):185-91. . View in PubMed
  • Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. . View in PubMed
  • Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86. . View in PubMed
  • Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. . View in PubMed
  • Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting Mol Interv. 2010 Aug; 10(4):197-203. . View in PubMed
  • Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in PubMed
  • Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLoS One. 2010 May 12; 5(5):e10471. . View in PubMed
  • Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 Cancer. 2010 Jan 15; 116(2):424-31. . View in PubMed
  • Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages Vaccine. 2009 Dec 30; 27 Suppl 6:G52-9. . View in PubMed
  • A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in PubMed
  • Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck. 2009 Nov; 31(11):1393-422. . View in PubMed
  • Immunogenicity of an HPV-16 L2 DNA vaccine Vaccine. 2009 Oct 30; 27(46):6432-4. . View in PubMed
  • Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors Clin Cancer Res. 2009 Oct 01; 15(19):6167-76. . View in PubMed
  • Sperm protein 17 is expressed in the sperm fibrous sheath J Transl Med. 2009 Jul 15; 7:61. . View in PubMed
  • Prostate stem cell antigen: a prospective therapeutic and diagnostic target Cancer Lett. 2009 May 18; 277(2):126-32. . View in PubMed
  • Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization Prostate. 2009 May 01; 69(6):571-84. . View in PubMed
  • Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol. 2009 May; 113(2):256-63. . View in PubMed
  • Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition Cancer Immunol Immunother. 2009 May; 58(5):719-28. . View in PubMed
  • Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16 J Immunol. 2009 Mar 01; 182(5):2919-28. . View in PubMed
  • Peptide-based vaccines for cancer: realizing their potential Expert Rev Vaccines. 2008 Dec; 7(10):1533-45. . View in PubMed
  • rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer Viral Immunol. 2008 Dec; 21(4):435-42. . View in PubMed
  • Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells J Transl Med. 2008 Oct 05; 6:56. . View in PubMed
  • Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells Oncogene. 2008 Oct 02; 27(44):5833-44. . View in PubMed
  • Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer J Immunother. 2008 Oct; 31(8):693-703. . View in PubMed
  • Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells Cancer Immunol Immunother. 2008 Jun; 57(6):789-97. . View in PubMed
  • Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines Cancer Immun. 2008 Apr 24; 8:8. . View in PubMed
  • A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev. 2008 Apr; 222:316-27. . View in PubMed
  • Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother. 2008 Mar; 57(3):303-15. . View in PubMed
  • AKAP-4: a novel cancer testis antigen for multiple myeloma Br J Haematol. 2008 Feb; 140(4):465-8. . View in PubMed
  • Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Res. 2008 Feb 01; 68(3):861-9. . View in PubMed
  • Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions Int J Cancer. 2008 Jan 15; 122(2):247-59. . View in PubMed
  • Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs Int Immunol. 2007 Oct; 19(10):1223-34. . View in PubMed
  • A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol. 2007 Sep; 106(3):558-66. . View in PubMed
  • Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity J Immunol. 2007 Jun 15; 178(12):7587-97. . View in PubMed
  • Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides J Transl Med. 2007 Jun 07; 5:26. . View in PubMed
  • Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. . View in PubMed
  • The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors Vaccine. 2007 Apr 30; 25(17):3437-44. . View in PubMed
  • Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax J Transl Med. 2007 Apr 23; 5:20. . View in PubMed
  • Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7 Clin Cancer Res. 2007 Apr 15; 13(8):2385-91. . View in PubMed
  • A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. . View in PubMed
  • In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer Cancer Res. 2007 Feb 01; 67(3):1344-51. . View in PubMed
  • Mechanisms used by human papillomaviruses to escape the host immune response Curr Cancer Drug Targets. 2007 Feb; 7(1):79-89. . View in PubMed
  • Therapeutic vaccination for HPV induced cervical cancers Dis Markers. 2007; 23(4):337-52. . View in PubMed
  • Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund’s adjuvant J Transl Med. 2006 Oct 23; 4:42. . View in PubMed
  • T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50. . View in PubMed
  • Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine. 2006 Jun 12; 24(24):5235-44. . View in PubMed
  • Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. . View in PubMed
  • Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma Hum Pathol. 2005 Dec; 36(12):1289-93. . View in PubMed
  • Vaccination Against Cervical Cancer: Hopes and Realities Am J Cancer (Auckl). 2005 Jul; 4(4):207-219. . View in PubMed
  • Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Hum Immunol. 2005 Jul; 66(7):762-72. . View in PubMed
  • Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation J Immunol. 2005 Jun 01; 174(11):7172-8. . View in PubMed
  • Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in PubMed
  • Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor Cancer Res. 2005 Feb 15; 65(4):1570-6. . View in PubMed
  • The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management Eur J Gynaecol Oncol. 2005; 26(2):129-42. . View in PubMed
  • Synopsis of the 6th Walker’s Cay Colloquium on Cancer Vaccines and Immunotherapy J Transl Med. 2004 Jun 22; 2(1):20. . View in PubMed
  • Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clin Cancer Res. 2004 May 15; 10(10):3301-8. . View in PubMed
  • Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors Oncogene. 2004 May 13; 23(22):3972-9. . View in PubMed
  • Sperm protein 17 is expressed in human somatic ciliated epithelia J Histochem Cytochem. 2004 Apr; 52(4):549-54. . View in PubMed
  • Peptide-based vaccines for cancer immunotherapy Expert Opin Biol Ther. 2004 Feb; 4(2):181-98. . View in PubMed
  • Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine. 2004 Jan 02; 22(3-4):520-7. . View in PubMed
  • Cure of glioma: a space not yet occupied for the lesion Cancer Invest. 2004; 22(3):479-80. . View in PubMed
  • Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo Blood. 2004 Jan 01; 103(1):177-84. . View in PubMed
  • Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes Cancer Invest. 2004; 22(3):417-34. . View in PubMed
  • Cancer immunotherapy: avoiding the road to perdition J Transl Med. 2004 07 29; 2(1):26. . View in PubMed
  • Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker’s Cay Cancer Immunol Immunother. 2003 Oct; 52(10):655-60. . View in PubMed
  • Is sperm protein 17 a useful target for tumor immunotherapy? Blood. 2003 Sep 15; 102(6):2308-9.. View in PubMed
  • Advances in prophylactic cancer vaccine research Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. . View in PubMed
  • Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine. 2003 Jul 04; 21(23):3219-27. . View in PubMed
  • Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in PubMed
  • Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation Vaccine. 2003 Jun 02; 21(19-20):2506-15. . View in PubMed
  • Recent progress in tumour vaccine development Expert Opin Investig Drugs. 2003 Jun; 12(6):971-81. . View in PubMed
  • CD4+ T cell matters in tumor immunity Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. . View in PubMed
  • HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation J Cell Physiol. 2003 Mar; 194(3):356-62. . View in PubMed
  • Advances in immunotherapy for prostate cancer Adv Cancer Res. 2003; 87:159-94. . View in PubMed
  • Cervical cancer vaccines: recent advances in HPV research Viral Immunol. 2003; 16(2):111-21. . View in PubMed
  • HPV protein/peptide vaccines: from animal models to clinical trials Front Biosci. 2003 Jan 01; 8:s81-91. . View in PubMed
  • Synopsis of the 4th Walker’s Cay Meeting on Cancer Vaccines, 7-10 March 2002 Cancer Immunol Immunother. 2002 Dec; 51(11-12):674-6. . View in PubMed
  • Emerging strategies in tumor vaccines Curr Opin Oncol. 2002 Nov; 14(6):641-8. . View in PubMed
  • Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res. 2002 Oct 15; 62(20):5792-9. . View in PubMed
  • The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells J Immunol. 2002 Oct 15; 169(8):4273-8. . View in PubMed
  • Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses J Immunol. 2002 Sep 15; 169(6):3242-9. . View in PubMed
  • Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells Nat Med. 2002 Sep; 8(9):979-86. . View in PubMed
  • Ins and outs of clinical trials with peptide-based vaccines Front Biosci. 2002 May 01; 7:e204-13. . View in PubMed
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy J Immunother. 2002 Mar-Apr; 25(2):97-138. . View in PubMed
  • Immunodominance and tumor escape Semin Cancer Biol. 2002 Feb; 12(1):25-31. . View in PubMed
  • Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells Am J Pathol. 2002 Feb; 160(2):521-8. . View in PubMed
  • The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy Adv Cancer Res. 2002; 86:113-48. . View in PubMed
  • Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention Intervirology. 2002; 45(4-6):300-7. . View in PubMed
  • T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A. 2001 Dec 04; 98(25):14565-70. . View in PubMed
  • Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in PubMed
  • Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res. 2001 Nov 01; 61(21):7861-7. . View in PubMed
  • Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice Cancer Res. 2001 Aug 01; 61(15):5857-60. . View in PubMed
  • Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo Cancer Res. 2001 Jul 15; 61(14):5499-504. . View in PubMed
  • Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide J Immunol. 2001 Jun 15; 166(12):7151-7. . View in PubMed
  • Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro J Immunol. 2001 May 15; 166(10):5917-24. . View in PubMed
  • Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol. 2001 May 01; 166(9):5366-73. . View in PubMed
  • Prospect for immunotherapy of acute lymphoblastic leukemia Leukemia. 2001 May; 15(5):701-6. . View in PubMed
  • Physical interaction of human papillomavirus virus-like particles with immune cells Int Immunol. 2001 May; 13(5):633-41. . View in PubMed
  • Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells J Immunol. 2001 May 01; 166(9):5398-406. . View in PubMed
  • Human T cell responses to endogenously presented HLA-A*0201 restricted peptides of Simian virus 40 large T antigen J Cell Biochem. 2001 Apr 2-27; 82(1):155-62. . View in PubMed
  • A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in PubMed
  • Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7 Clin Cancer Res. 2001 Mar; 7(3 Suppl):788s-795s. . View in PubMed
  • Tracking the common ancestry of antigenically distinct cancer variants Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s. . View in PubMed
  • Cervical cancer vaccines: emerging concepts and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in PubMed
  • Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice Virology. 2001 Jan 05; 279(1):354-60. . View in PubMed
  • A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin Cancer Res. 2000 Sep; 6(9):3406-16. . View in PubMed
  • Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother. 2000 Mar-Apr; 23(2):255-66. . View in PubMed
  • Notch signaling as a target in multimodality cancer therapy Curr Opin Mol Ther. 2000 Feb; 2(1):55-65. . View in PubMed
  • Successful immunotherapy of an intraocular tumor in mice Cancer Res. 1999 Oct 15; 59(20):5250-4. . View in PubMed
  • Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia. 1999 Aug; 13(8):1188-99. . View in PubMed
  • Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial Eur J Cancer. 1999 Jun; 35(6):946-52. . View in PubMed
  • Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response J Cell Biochem. 1999 May 01; 73(2):145-52. . View in PubMed
  • Modulation of the immune response and tumor growth by activated Ras Leukemia. 1999 Apr; 13(4):502-13. . View in PubMed
  • Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles Biol Chem. 1999 Mar; 380(3):335-40. . View in PubMed
  • Papillomavirus virus-like particles as anticancer vaccines Curr Opin Mol Ther. 1999 Feb; 1(1):82-8. . View in PubMed
  • Differential binding of viral peptides to HLA-A2 allelesImplications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. . View in PubMed
  • Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch Virol. 1999; 144(7):1323-43. . View in PubMed
  • Active immunization against cancer cells: impediments and advances Semin Oncol. 1998 Dec; 25(6):697-706. . View in PubMed
  • Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope J Immunother. 1998 Nov; 21(6):399-408. . View in PubMed
  • L1-specific protection from tumor challenge elicited by HPV16 virus-like particles Virology. 1998 Oct 25; 250(2):371-6. . View in PubMed
  • Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res. 1998 Jul 15; 58(14):3094-100. . View in PubMed
  • PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired J Immunother. 1998 Jul; 21(4):317-22. . View in PubMed
  • Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells J Immunol. 1998 May 01; 160(9):4449-56. . View in PubMed
  • The detection of simian virus 40 in human tumors by polymerase chain reaction Monaldi Arch Chest Dis. 1998 Apr; 53(2):202-10. . View in PubMed
  • Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. . View in PubMed
  • The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans Monaldi Arch Chest Dis. 1998 Apr; 53(2):193-7. . View in PubMed
  • Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1800-5. . View in PubMed
  • Identification of peptides for immunotherapy of cancerIt is worth the effort. Crit Rev Immunol. 1998; 18(1-2):7-27. . View in PubMed
  • Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas Dev Biol Stand. 1998; 94:33-40. . View in PubMed
  • Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target J Immunol. 1997 Dec 01; 159(11):5545-9. . View in PubMed
  • Activation or frustration of anti-tumor responses by T-cell-based immune modulation Semin Immunol. 1997 Oct; 9(5):323-7. . View in PubMed
  • HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS J Immunol. 1997 Oct 01; 159(7):3648-54. . View in PubMed
  • Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product Int J Cancer. 1997 Sep 26; 73(1):125-30. . View in PubMed
  • Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes J Exp Med. 1997 Aug 29; 186(5):695-704. . View in PubMed
  • Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes Cancer Lett. 1997 Jun 03; 116(1):93-101. . View in PubMed
  • The current status of therapeutic HPV vaccine Ann Med. 1996 Dec; 28(6):471-7. . View in PubMed
  • Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity Transplantation. 1996 Nov 27; 62(10):1485-91. . View in PubMed
  • Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity Immunotechnology. 1996 Nov; 2(4):241-51. . View in PubMed
  • Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer Clin Cancer Res. 1996 Nov; 2(11):1825-8. . View in PubMed
  • Peptide-based cancer vaccines Curr Opin Immunol. 1996 Oct; 8(5):651-7. . View in PubMed
  • Protective antitumor immunity induced by immunization with completely allogeneic tumor cells Cancer Res. 1996 Aug 15; 56(16):3782-7. . View in PubMed
  • Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):7855-60. . View in PubMed
  • Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer. 1996 May 29; 66(5):686-91. . View in PubMed
  • Enhanced tumor outgrowth after peptide vaccinationFunctional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. . View in PubMed
  • Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability J Immunol. 1996 May 01; 156(9):3308-14. . View in PubMed
  • Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope Cancer Res. 1996 Feb 01; 56(3):582-8. . View in PubMed
  • Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med. 1995 Dec; 1(12):1297-302. . View in PubMed
  • An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsIdentification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec; 44(4):189-98. . View in PubMed
  • Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors Eur J Immunol. 1995 Sep; 25(9):2638-42. . View in PubMed
  • Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape Biochem Soc Trans. 1995 Aug; 23(3):692-6. . View in PubMed
  • The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):77-85. . View in PubMed
  • Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. . View in PubMed
  • Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells J Exp Med. 1995 Jul 01; 182(1):163-74. . View in PubMed
  • Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization Immunol Lett. 1995 Jul-Aug; 47(1-2):1-8. . View in PubMed
  • Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2 Cancer Res. 1995 Jun 15; 55(12):2627-34. . View in PubMed
  • Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides J Immunol. 1995 Jun 01; 154(11):5934-43. . View in PubMed
  • T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes Immunol Rev. 1995 Jun; 145:167-77. . View in PubMed
  • MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells J Immunol. 1995 Jun 01; 154(11):5715-24. . View in PubMed
  • Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201 Int J Cancer. 1995 May 04; 61(3):389-96. . View in PubMed
  • A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs Hum Immunol. 1995 May; 43(1):13-8. . View in PubMed
  • Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay Hum Immunol. 1995 May; 43(1):1-12. . View in PubMed
  • CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells J Immunol. 1995 Apr 15; 154(8):3991-8. . View in PubMed
  • An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol. 1995 Apr 01; 154(7):3396-405. . View in PubMed
  • Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase AIDS. 1995 Feb; 9(2):121-7. . View in PubMed
  • Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences J Immunol. 1995 Feb 01; 154(3):1273-9. . View in PubMed
  • Class I MHC-peptide interactions: structural requirements and functional implications Cancer Surv. 1995; 22:37-49. . View in PubMed
  • Functional and ultrastructural aspects of antigen processing by dendritic cells Adv Exp Med Biol. 1995; 378:227-31. . View in PubMed
  • The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes J Immunol. 1994 Dec 15; 153(12):5586-92. . View in PubMed
  • Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity Mol Immunol. 1994 Dec; 31(18):1391-401. . View in PubMed
  • Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice J Virol. 1994 Sep; 68(9):6038-46. . View in PubMed
  • Tumor rejection antigens and tumor specific cytotoxic T lymphocytes Behring Inst Mitt. 1994 Jul; (94):72-86. . View in PubMed
  • p53, a potential target for tumor-directed T cells Immunol Lett. 1994 May; 40(2):171-8. . View in PubMed
  • Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins J Immunol. 1994 Apr 15; 152(8):3904-12. . View in PubMed
  • Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):119-28. . View in PubMed
  • Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides Ciba Found Symp. 1994; 187:97-104; discussion 104-12. . View in PubMed
  • Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing Eur J Immunol. 1993 Dec; 23(12):3082-8. . View in PubMed
  • Potential immunogenicity of oncogene and tumor suppressor gene products Curr Opin Immunol. 1993 Oct; 5(5):709-13. . View in PubMed
  • In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53 Eur J Immunol. 1993 Sep; 23(9):2072-7. . View in PubMed
  • Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells Eur J Immunol. 1993 Sep; 23(9):2242-9. . View in PubMed
  • Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. . View in PubMed
  • Human leukocyte antigen-A21 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):115-20. . View in PubMed
  • In vivo detection of fluorescent tumor-specific cytotoxic T cell clones J Immunol Methods. 1993 Jul 06; 163(1):23-32. . View in PubMed
  • Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection J Virol. 1993 Jul; 67(7):4182-9. . View in PubMed
  • Identification of peptide sequences that potentially trigger HLA-A21-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun; 23(6):1215-9. . View in PubMed
  • Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination Eur J Immunol. 1993 May; 23(5):1189-92. . View in PubMed
  • The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture Adv Exp Med Biol. 1993; 329:185-9. . View in PubMed
  • Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses Eur J Immunol. 1992 Nov; 22(11):3013-20. . View in PubMed
  • A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation J Immunol Methods. 1992 Oct 19; 155(1):101-11. . View in PubMed
  • Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line Eur J Immunol. 1992 Jun; 22(6):1639-42. . View in PubMed
  • Lessons from T cell responses to virus induced tumours for cancer eradication in general Cancer Surv. 1992; 13:81-99. . View in PubMed
  • Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses Eur J Immunol. 1991 Dec; 21(12):2963-70. . View in PubMed
  • Pretransplantation blood transfusion revisited N Engl J Med. 1991 Oct 24; 325(17):1210-3. . View in PubMed
  • In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes Immunol Lett. 1991 Oct; 30(2):229-32. . View in PubMed
  • Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms Semin Cancer Biol. 1991 Oct; 2(5):347-54. . View in PubMed
  • T-cell immunotherapy of cancer Res Immunol. 1991 Jun-Aug; 142(5-6):425-9. . View in PubMed
  • Peptide selection by MHC class I molecules Nature. 1991 Apr 25; 350(6320):703-6. . View in PubMed
  • Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2283-7. . View in PubMed
  • Mechanisms of transplantation tolerance: do anti-idiotypic antibodies play a role? Transplant Proc. 1991 Feb; 23(1 Pt 1):155-6.. View in PubMed
  • Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding Int J Cancer Suppl. 1991; 6:90-4. . View in PubMed
  • Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens Hum Immunol. 1990 Nov; 29(3):220-8. . View in PubMed
  • Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells J Immunol. 1990 Oct 01; 145(7):2254-9. . View in PubMed
  • Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro Cell. 1990 Aug 10; 62(3):563-7. . View in PubMed
  • Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells EMBO J. 1990 Aug; 9(8):2621-9. . View in PubMed
  • Efficacy of cytotoxic T lymphocytes against virus-induced tumors Cancer Cells. 1990 Apr; 2(4):116-20. . View in PubMed
  • Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatchDifferent mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur J Immunol. 1990 Feb; 20(2):441-4. . View in PubMed
  • Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes Cell. 1989 Nov 17; 59(4):603-14. . View in PubMed
  • Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors Transplantation. 1989 Nov; 48(5):844-7. . View in PubMed
  • Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells J Immunol. 1989 Jun 01; 142(11):4113-7. . View in PubMed
  • Transfusion-induced skin allograft enhancement across an H-2 class-I mismatch is caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors within the allograft Transplant Proc. 1989 Feb; 21(1 Pt 1):1169-70. . View in PubMed
  • Immunosurveillance of virus-induced tumors Cold Spring Harb Symp Quant Biol. 1989; 54 Pt 1:597-603. . View in PubMed
  • Mechanism of skin allograft enhancement across an H-2 class I mutant differenceEvidence for involvement of veto cells. Eur J Immunol. 1988 Dec; 18(12):2105-8. . View in PubMed
  • Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells J Immunol. 1988 May 01; 140(9):3186-93. . View in PubMed
  • Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Ann N Y Acad Sci. 1988; 532:280-91. . View in PubMed
  • Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells Eur J Immunol. 1987 Apr; 17(4):471-5. . View in PubMed
  • Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infectionProtection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. . View in PubMed
  • Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function Immunogenetics. 1986; 24(4):267-74. . View in PubMed
  • Abolition of specific immune response defect by immunization with dendritic cells Nature. 1985 Nov 7-13; 318(6041):59-62. . View in PubMed
  • Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells J Exp Med. 1984 Dec 01; 160(6):1752-66. . View in PubMed
  • Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants Transplant Proc. 1983 Dec; 15(4):2086-9. . View in PubMed
  • Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants J Immunol. 1983 Mar; 130(3):1090-6. . View in PubMed
  • The peroxidation of thiocyanate catalysed by myeloperoxidase and lactoperoxidase Biochim Biophys Acta. 1982 Dec 20; 709(2):212-9. . View in PubMed

Similar People